139 related articles for article (PubMed ID: 38206039)
1. Letter: Diffuse Isocitrate Dehydrogenase-Mutant Gliomas With Histone H3 Alterations are Distinguished by Unique Clinical Characteristics, Molecular Expression Profile, and Survival Prognosis.
Rahman S; Ahmed Khan R; Chowdhury M; Hasan M; Haque MR; Rahman MM
Neurosurgery; 2024 Apr; 94(4):e59-e60. PubMed ID: 38206039
[No Abstract] [Full Text] [Related]
2. Commentary: Diffuse Isocitrate Dehydrogenase-Mutant Gliomas With Histone H3 Alterations Are Distinguished by Unique Clinical Characteristics, Molecular Expression Profile, and Survival Prognosis.
Blobner J; Tonn JC
Neurosurgery; 2023 Oct; 93(4):e92. PubMed ID: 37186882
[No Abstract] [Full Text] [Related]
3. Diffuse Isocitrate Dehydrogenase-Mutant Gliomas With Histone H3 Alterations Are Distinguished by Unique Clinical Characteristics, Molecular Expression Profile, and Survival Prognosis.
Cheng C; Wang D; Yu M; Zhai Y; Pan C; Liang B; Zhang J; Wang C; Yin Y; Li L; Wu F; Shi Z; Fan X; Liu X; Wang Z; Zhao Z; Li G; Jiang T; Zhang W;
Neurosurgery; 2023 Oct; 93(4):802-812. PubMed ID: 37070826
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of H3 K27M-mutant gliomas in adults.
Meyronet D; Esteban-Mader M; Bonnet C; Joly MO; Uro-Coste E; Amiel-Benouaich A; Forest F; Rousselot-Denis C; Burel-Vandenbos F; Bourg V; Guyotat J; Fenouil T; Jouvet A; Honnorat J; Ducray F
Neuro Oncol; 2017 Aug; 19(8):1127-1134. PubMed ID: 28201752
[TBL] [Abstract][Full Text] [Related]
5. Histone H3.3 G34-mutant Diffuse Gliomas in Adults.
Wang L; Shao L; Li H; Yao K; Duan Z; Zhi C; Song S; Cheng Y; Wang F; Wang W; Piao Y; Gui Q; Lu D; Qi X; Teng L
Am J Surg Pathol; 2022 Feb; 46(2):249-257. PubMed ID: 34352809
[TBL] [Abstract][Full Text] [Related]
6. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.
Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A
Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431
[TBL] [Abstract][Full Text] [Related]
7. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
8. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant.
Louis DN; Giannini C; Capper D; Paulus W; Figarella-Branger D; Lopes MB; Batchelor TT; Cairncross JG; van den Bent M; Wick W; Wesseling P
Acta Neuropathol; 2018 Apr; 135(4):639-642. PubMed ID: 29497819
[No Abstract] [Full Text] [Related]
9. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
10. ATRX immunostaining predicts IDH and H3F3A status in gliomas.
Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
[TBL] [Abstract][Full Text] [Related]
11. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
[TBL] [Abstract][Full Text] [Related]
12. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
[TBL] [Abstract][Full Text] [Related]
13. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
[TBL] [Abstract][Full Text] [Related]
14. Overview of DNA methylation in adult diffuse gliomas.
Aoki K; Natsume A
Brain Tumor Pathol; 2019 Apr; 36(2):84-91. PubMed ID: 30937703
[TBL] [Abstract][Full Text] [Related]
15. Molecular Pathology of Gliomas.
Galbraith K; Snuderl M
Surg Pathol Clin; 2021 Sep; 14(3):379-386. PubMed ID: 34373090
[TBL] [Abstract][Full Text] [Related]
16. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Malzkorn B; Reifenberger G
Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
[TBL] [Abstract][Full Text] [Related]
17. H3 K27M-mutant diffuse midline gliomas in different anatomical locations.
Wang L; Li Z; Zhang M; Piao Y; Chen L; Liang H; Wei Y; Hu Z; Zhao L; Teng L; Lu D
Hum Pathol; 2018 Aug; 78():89-96. PubMed ID: 29727696
[TBL] [Abstract][Full Text] [Related]
18. The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation.
Chai RC; Zhang YW; Liu YQ; Chang YZ; Pang B; Jiang T; Jia WQ; Wang YZ
Acta Neuropathol Commun; 2020 Mar; 8(1):40. PubMed ID: 32228694
[TBL] [Abstract][Full Text] [Related]
19. Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas.
Schiff D; Purow BW
Nat Rev Neurol; 2009 Jun; 5(6):303-4. PubMed ID: 19498431
[TBL] [Abstract][Full Text] [Related]
20. Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.
Hodges TR; Choi BD; Bigner DD; Yan H; Sampson JH
J Neurosurg; 2013 Jun; 118(6):1176-80. PubMed ID: 23581583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
